If you or someone you know is taking Tysabri and experiencing new neurological symptoms, it's natural to worry about the risk of progressive multifocal leukoencephalopathy (PML). Distinguishing early PML symptoms from other conditions is critical for timely intervention. The medical community has long studied how to identify and confirm PML in patients on disease-modifying therapies, and this page breaks down the key symptoms and diagnostic steps.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Texas who have developed PML after Tysabri exposure, understanding the medical evidence linking the drug to this harm, as well as the legal framework for potential settlement claims, is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the JC virus in immunocompromised individuals, and Tysabri's mechanism—blocking lymphocyte migration into the central nervous system—impairs immune surveillance, allowing the virus to proliferate unchecked. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and ataxia. Diagnosis relies on MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition usually leads to severe disability or death, as noted in the boxed warning.
The FDA-approved labeling mandates that Tysabri be prescribed only through the TOUCH Prescribing Program, a restricted distribution system designed to monitor patients for PML. Healthcare professionals are required to evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also submit periodic status reports and report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these monitoring requirements, questions about the adequacy of warnings have arisen in litigation. The boxed warning clearly states that Tysabri increases PML risk and that factors such as anti-JCV antibody status, duration of therapy, and prior immunosuppressant use should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and their families have alleged that these warnings were insufficient to fully convey the magnitude of risk or that healthcare providers did not adequately communicate them. For affected patients in Texas, settlement considerations may include the severity of PML-related harm, the duration of Tysabri exposure, and whether the patient had known risk factors that were not properly addressed.
The latency period between Tysabri initiation and PML diagnosis varies. The labeling notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases have been reported after as few as 12 months of therapy, but the majority occur after 24 months or more. Once PML develops, neurological deterioration can be rapid, often leading to permanent disability or death within weeks to months. The TOUCH program requires monitoring for new signs or symptoms suggestive of PML, and dosing should be withheld immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early detection through MRI and CSF analysis is critical, but even with prompt diagnosis, outcomes are often poor.
For patients in Texas considering a legal claim related to Tysabri-associated PML, the statute of limitations is a key factor. Texas law generally allows two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered, to file a personal injury lawsuit. For PML, the date of discovery is often the date of diagnosis. However, because PML can cause progressive cognitive decline, the discovery rule may extend the filing window if the patient was unable to recognize the injury earlier. Given the severity of PML and the potential for delayed diagnosis, affected individuals should consult with a Texas attorney experienced in pharmaceutical litigation to determine their specific filing deadline. Settlement negotiations may occur outside of litigation, but any settlement agreement would need to be finalized before the statute of limitations expires.
The medical evidence clearly establishes that Tysabri increases the risk of PML, a devastating brain infection. The FDA-approved labeling provides detailed warnings and mandates a strict monitoring program, but questions about the adequacy of those warnings persist. For Texas patients who have developed PML after Tysabri exposure, understanding the risk factors, the timeline of harm, and the applicable statute of limitations is essential for pursuing any settlement or legal claim. Prompt legal consultation is recommended to preserve rights and ensure compliance with Texas filing deadlines.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Texas law generally allows two years from the date of injury or discovery of injury to file a personal injury lawsuit. For PML, the discovery date is typically the diagnosis date. However, due to cognitive decline, the discovery rule may extend the deadline. Consult a Texas attorney for your specific situation.
Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants. These are outlined in the FDA labeling (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Diagnosis involves MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early detection is critical but outcomes are often poor.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.